|
|
|
|
 |
| April 5, 2012 | ISSUE NUMBER 245 VOL 8 |
|
Special Report
Obamacare's Effect on Drug Spending
Provisions in the US’s Affordable Care Act drove out-of-pocket costs down, while increasing drug spending among 19 to 25-year olds in 2011, according to IMS research published on last week...Read More
Comment
IP: Time for a Reset?
IP must adapt to new ways of extracting value from assets the industry never knew it had, beginning with a more robust defense of data exclusivity, writes William Looney ...Read More
Healthcare
Should Smokers Cough Up the Money for Cancer Research?
This June, Californians will be asked whether cigarette smokers should subsidize research to treat diseases related to smoking cigarettes. Ben Comer reports ...Read More
Advertisement
CBI's Bio/Pharma Regulatory Policy Exchange
May 7-8, 2012
Washington, D.C.
Prepare for a new wave of legislative and regulatory policies that will shape the life sciences industry for years to come.
Learn best practices on how the shifting regulatory and policy landscape will affect the biopharma industry going forward with Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Eisai, Eli Lilly and Company, EMD Serono, Merck, Novartis and Shire Pharmaceuticals!
Register by March 10th at  www.cbinet.com/policyexchange and save $300 with priority code: QSS925
|
Global
Fighting the Pain in Spain (and Beyond)
Pharm Exec talks to Carlos Plata, Chief Scientific Officer of Esteve, the Spanish company that is trying to rise above the economic gloom to become a major player in pain
...Register here
Advertisement
CBI's 4th Annual Summit on Clinical Trial Investigator Portals
May 15-16, 2012 * Philadelphia, PA
Provide High-Quality Data to Study Teams for Real-Time Reporting
Learn best practices in utilizing clinical portals for efficient study start-up reducing trial costs workload of clinical investigator sites with Merck & Co., Inc., Quintiles, GlaxoSmithKline, and more!!! Register by May 15, 2012 at  www.cbinet.com/portals and save $300 with priority code: GMA284
|
|
|
|
 // AstraZeneca (AZ) appointed Dr Mike Poole to lead its new 'virtual' neuroscience Innovative Medicines Unit.
// Merck appointed Michael Holston to succeed Richard Bowles as Chief Ethics and Compliance Officer. // Dan Zabrowski became Head of Roche Applied Science in its diagnostics division. // Jacob Tolstrup moved from Vice President of Finance and Administration at Lundbeck US to a new role responsible for business development, based at the company's Valby, Denmark, headquarters.
|
|
Advertisement
Utilization of Rasch Measurement Models for Assessing Validity: A Mixed Methods Approach
On-Demand Webcast
 Click here |
|
|
|
|
|
|
 |
|
|
 |
 |
|
 |
What do you see as the chief obstacle to achieving growth in the emerging markers?
|
|
|
|
|
You
are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To
ensure delivery to your Inbox, please add us to your
address book. If you need help doing this, click
here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
